India Continuous Glucose Monitoring (CGM) Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Overview

India Continuous Glucose Monitoring (CGM) Market Snapshot & Metrics Overview

Study Period	2020 - 2032
Forecast Data Period	2027 - 2032
Base Year Market Size (2026)	USD 231.40 Million
Market Size (2027)	USD 258.10 Million
Market Size (2032)	USD 452.90 Million
Growth Rate (2027 - 2032)	11.90 %
Market Concentration	Medium
Major Players* Roche Dexcom Ascensia Medtronic Abbott Laboratories	*Disclaimer: Major Players sorted in no particular order

• Asia
• Australia
• Europe
• Japan
• Latin America
• Middle East and Africa
• New Zealand
• North America
• South Korea

Market Trends and Insights

Soaring Diabetes Prevalence & Earlier Diagnosis

The diagnosed diabetes population gives CGM suppliers a substantial clinical audience, while screening broadens the opportunity for assessment. India's National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) reported 6.41 million registered diabetes patients continuing treatment in January-June 2025, with the same count recorded as diagnosed.^[1] It also recorded 360.5 million cumulative diabetes screening events through October 31, 2025, at rural and urban Sub-Health Centers and Primary Health Centers, including Ayushman Arogya Mandirs. Screening creates a point for considering monitoring needs, while the treatment count identifies an established clinical population. Registered patients are already in ongoing treatment, so repeat monitoring is a more immediate commercial prospect in the India Continuous Glucose Monitoring Market than the volume of screening events alone.

Rapid Expansion of Tele-Consult & Digital-Health Programs

Digital diabetes programs create a route for CGM data to become part of a continuing care service. By December 2025, Fitterfly, a division of PB Health, reported that its technology drew on more than 1 million CGM readings and powered diabetes-care programs with cumulative reach exceeding 40,000 people. The Research Society for the Study of Diabetes in India (RSSDI) also launched rural screening, treatment follow-up and digital-health outreach on August 15, 2026. These activities connect data-based care with a broader effort to reach patients beyond specialist visits. The commercial opening in the India Continuous Glucose Monitoring Market is selective sensor supply within digital care programs, where glucose-pattern assessment can support a service offered to a broader diabetes population.

Growing Penetration of Insurance-Led RPM Contracts

Insurance-led remote patient monitoring can expand CGM demand by moving the funding decision into a defined care benefit. For an insurer, the commercial design would need to identify the patients receiving sensors and connect their readings with covered follow-up. Linking a patient group to repeated device provision could make continued monitoring part of the contracted service. The addressable device opportunity would depend on coverage duration and the responsibilities assigned to the insurer, care provider and supplier. Under a contract funding clinical contact without sensor provision, direct hardware demand would be limited and explicit device coverage would be decisive.

Domestic Sensor Assembly Lowering ASPs

Domestic sensor assembly offers a potential affordability mechanism when production savings translate into a lower selling price. A supplier considering local assembly would need to balance unit costs against the throughput required to maintain consistent sensor production. For continued monitoring, the relevant buyer benefit would be a sustainable reduction in repeated sensor spending. Pricing decisions would determine how much of an assembly saving reaches patients and how much remains with the supplier. An assembly saving would have its strongest demand effect when the resulting price reduction lets a patient afford another monitoring period.

High Upfront Device Cost vs SMBG

High device costs constrain the transition from interest in continuous monitoring to sustained use in India. A February 2026 narrative review, covering literature through September 2025, identified high costs, shorter sensor life, limited options and predominantly urban and semi-urban availability as affordability barriers.^[2] Together, these constraints make the commercial hurdle broader than the price of obtaining a first device. For a household considering repeated monitoring, a shorter usable sensor life makes the replacement commitment relevant to the initial decision. Suppliers therefore face an affordability threshold tied to continuity of use, with the remaining expense limiting the addressable pool of sustained purchasers.

Patchy Reimbursement Outside Tier-1 Cities

Reimbursement determines whether clinical suitability can translate into a funded device purchase beyond individual household spending. A 2026 review reported no national CGM reimbursement pathway in India and no coverage under Ayushman Bharat, ESI or most state insurance schemes. This leaves a commercial distinction between identifying a patient who could benefit and identifying a payer for that patient's monitoring. Broader institutional access therefore requires a financing route as well as a clinical rationale. Scheme exclusion presents a separate obstacle to paid use even when the device price is acceptable.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

India Continuous Glucose Monitoring (CGM) Market Segment Analysis

Sensors accounted for a 59.16% share of the India continuous glucose monitoring (CGM) market size in 2026, making them the largest segment. Abbott Healthcare Private Limited reduced the listed MRP of its FreeStyle Libre Sensor in India effective September 22, 2025, as its GST rate fell from 18% to 5% under Notification No. 09/2025-Central Tax (Rate). The price revision lowers the listed cost of starting a monitoring episode. Because sensors are consumables replaced on a recurring wear cycle, the lower listed MRP also applies at each replacement purchase.

Receivers are the fastest-growing segment, with a forecast CAGR of 12.7% over 2027-2032. Abbott's listed MRP for the FreeStyle Libre Reader fell from INR 5,774 (USD 65.57) through September 21, 2025, to INR 5,413 (USD 61.47) effective September 22, 2025. The reader's listed GST rate changed from 12% to 5%. The dedicated reader creates an initial equipment purchase, so the lower listed MRP addresses entry into monitoring while replacement-sensor spending determines the ongoing commitment.

Real-time CGM (rtCGM) represented a 59.99% India continuous glucose monitoring (CGM) market share in 2026, making it the largest segment. The Indian Council of Medical Research (ICMR) 2022 type 1 diabetes guideline describes personal, unmasked real-time CGM as allowing patients or caregivers to assess glucose fluctuations and take remedial action. The same guideline cautions that the terms continuous and real-time are relatively inaccurate because sensors record glucose every 5 to 15 minutes and interstitial glucose lags blood glucose by approximately 7-15 minutes. The clinical use case is patient access to readings that can inform a response to a changing pattern. Those timing limits make the pattern of glucose change central to interpreting a reading when patients or caregivers consider remedial action.

Intermittently scanned CGM is the fastest-growing segment, with a forecast CAGR of 12.5% over 2027-2032. Its commercial case can be organized around user-initiated readings and defined monitoring periods, matching the device offer to a review the patient wants to undertake. A supplier could link a scan with a specific food, activity or treatment question, giving use a clear purpose. Adoption would depend on whether that interaction suits the patient's care routine and the clinician's expectations for reviewing glucose data. Sustained interaction constrains the commercial opportunity when repeat sensor use depends on a patient choosing to scan across the assessment period.

Type 1 diabetes was the largest segment, accounting for 69.35% of revenue in 2026. RSSDI's 2025 consensus for children, adolescents and young adults describes CGM pattern and variability data as helpful for insulin titration and assessing responses. That gives monitoring a treatment-related role, with the device's usefulness linked to interpreting changes in glucose rather than collecting readings alone. Sensor provision can therefore be organized around repeated assessment of a patient's response to insulin adjustments. The recommendation to make CGM available from diagnosis supports an initiation offer followed by repeat sensor supply when insulin responses need reassessment.

Type 2 diabetes is the fastest-growing segment, with a forecast CAGR of 13.9% over 2027-2032. Researchers retrospectively analyzed Abbott FreeStyle Libre reports from 362 Indian patients with type 2 diabetes recorded from July 2024 to June 2025. Mean glucose was 170.2 mg/dL, and glucose remained above 200 mg/dL from 10 a.m. to midnight in most glucose management indicator categories (p<0.0001). These prolonged elevations give care teams a reason to examine when monitoring will inform meal-related or treatment decisions. The commercial opportunity is structured CGM use around periods of poor control, where the data can identify daily windows requiring clinical attention.

Adults were the largest segment, accounting for 66.4% of revenue in 2026. A case report published in 2025 from northern India described a 46-year-old man with chronic liver disease using CGM. This example connects adult monitoring with a complex clinical condition, where glucose information has to be interpreted alongside the patient's broader care. That setting favors an offer organized around a defined clinical problem and the professionals reviewing the readings.

Pediatrics is the fastest-growing segment, with a forecast CAGR of 14.7% over 2027-2032. Abbott launched FreeStyle Libre 2 Plus in India on August 21, 2025, offering the CGM sensor to adults and children aged 2 and above.^[3] This eligibility gives care teams an option extending from early childhood through adolescence, making age coverage part of developing a longer-term monitoring approach. The commercial challenge is converting eligibility into a care-supported monitoring routine, so that first sensor access can lead to a clinically useful pattern of continued use.

Home-care settings were the largest segment, representing 61.12% of revenue in 2026. RSSDI's India-specific consensus describes personal CGM as displaying real-time glucose levels, guiding insulin adjustments and alerting patients to extreme excursions. That patient-facing function gives self-management an operational role alongside review by clinicians. A home-care device proposition can therefore center on making readings useful between appointments, with a clear path for responding to the information. Clear instructions on readings and escalation therefore become part of a useful home-care offer, because patient-facing alerts shift part of the monitoring response to the user.

Sports and fitness centers are the fastest-growing segment, with a forecast CAGR of 15.8% over 2027-2032. Their device opportunity would depend on connecting glucose information to a defined training or nutrition question, with monitoring offered as a specific program component. Hospitals and clinics have a distinct professional-review role, with ICMR's type 1 diabetes guidance describing retrospective, professional CGM data being downloaded and subsequently reviewed in clinics. These settings create different supplier propositions, one built around an optional activity-focused service and another around clinician-led assessment of a patient's glucose record.

Geography Analysis

In North India, a quaternary-care example connects clinical capability with patient resources. A 2025 case series from one northern Indian quaternary care center described CGM use in 4 patients across clinical conditions, including observations in 2024, with most patients having higher socioeconomic status and adequate literacy. Such a setting makes interpretation support relevant to the device offer, because clinical complexity and the ability to use readings need to be addressed together. Specialist-led introduction fits this setting, provided sensor provision comes with support suited to the patient's circumstances.

South India offers a Chennai delivery example that pairs glucose information with access to clinical advice. In June 2025, Kauvery Hospital reported that its Chennai diabetes helpline, serving patients across Tamil Nadu, had enrolled a pregnant woman with gestational diabetes in a CGM program with real-time insulin and diet guidance. The operating link was between the helpline and clinical guidance, giving device use a defined management context. The helpline, launched on April 21, 2021 and reported at 1,500 days of uninterrupted round-the-clock service, gives the CGM enrollment an established advice service as its setting.

Lucknow provides a distinct example of professional CGM within outpatient assessment in Uttar Pradesh. From September 2024 to August 2025, Prasad Institute of Medical Sciences in Lucknow recruited 50 adults with type 2 diabetes for a prospective outpatient cohort using 14-day professional CGM to assess glycemic variability. The defined monitoring period places the device within a structured clinical episode. A comparable service offer could connect sensor provision to a specific assessment question and subsequent clinical review. This makes the defined assessment period a potential unit of sensor demand, with repeat supply tied to further clinical need.

Regulatory Framework and Outlook

The comparison covers selected jurisdictions from the perspective of CGM device sellers and distributors, placing India's national framework alongside its application in Uttar Pradesh. Sellers without a Rule 87(1) sale license who deal exclusively in medical devices must use the MD-41 application route to obtain MD-42 registration from the State Licensing Authority. Uttar Pradesh's Drug Controller is identified as the State Licensing Authority within the Food Safety and Drugs Administration. The commercial task is therefore to establish the applicable licensing route and responsible authority before device sales begin.

In India, the August 2026 amendment's recognition of MD-42 preserves a formal registration route with document scrutiny, supporting a Medium rating. Uttar Pradesh also merits Medium because Invest UP identified medical-device-sale registration as a pre-operation service of the state's Food Safety and Drugs Administration, consistent with the national seller-registration route. The August 2026 amendment also requires manufacturers outsourcing sterilization to a licensed facility to show that site's license number on labels, with compliance mandatory 6 months after August 14, 2026. It leaves the seller-registration application requirement for distributors and the MD-41/MD-42 route unchanged, supporting No change in both columns.

Value Chain Stages

The comparison follows CGM systems from supplier provision through import, distribution and retail fulfillment in India. At the system-provision stage, Tracky, DrStore Healthcare Services' healthtech brand, launched a Bluetooth-enabled CGM with a sensor, transmitter and mobile app in India on June 5, 2025. Abbott Healthcare Private Limited imports and markets FreeStyle Libre in India, linking the import stage's sales income to branded device supply. Bizcura Analytics LLP is GlucoRx Healthcare Pvt. Ltd.'s authorized distributor in India, placing downstream device sales at the distribution stage.

ColMed Innovations' retail responsibilities include invoicing, dispatch and after-sales support, bringing several customer-facing handoffs within one seller. That combination makes downstream execution commercially relevant even when the importer retains the product-marketing role. Future channel development can therefore capture value by coordinating replacement supply and issue resolution, while preserving clear responsibility for the connected system itself.

Key Opportunities for Market Participants

The comparison identifies CGM device opportunities for children, adolescents and young adults receiving diabetes care in India. RSSDI's 2025 consensus says CGM should ideally be available from type 1 diabetes diagnosis to track glucose patterns and the effects of diet, exercise and stress. It also identifies food response, activity and overnight glucose patterns as inputs for nutrition and activity planning. These recommendations give suppliers specific clinical uses around which to develop adoption offers.

The strongest opening is CGM adoption organized around the daily decisions of younger patients and their families. RSSDI recommends nutrition education from a qualified dietitian experienced in childhood diabetes and says online expert help may be sought. Aligning sensor provision with that expertise gives younger patients and families a route to act on meal and activity feedback.